Leukocytes and PRP

Understanding Leukocyte-Rich vs. Leukocyte-Poor PRP

The optimal leukocyte concentration in platelet-rich plasma (PRP) remains an area of active discussion within regenerative medicine. While published research continues to evolve, Alocuro’s system gives clinicians the flexibility to prepare leukocyte-rich, leukocyte-reduced, or baseline leukocyte PRP from a single device, allowing protocols to be adapted to each clinical application.

Alocuro’s Current Recommendations

Based on published evidence and extensive clinical feedback from Australian users, Alocuro recommends:

PRP Type	Recommended Use
Leukocyte-rich PRP (LR-PRP)	Chronic wound healing and skin PRP procedures with an infective component (e.g. active acne).
Baseline leukocyte concentration PRP	Acute tendon and muscle tears; skin; hair; erectile dysfunction; female GU PRP; fertility procedures.
Leukocyte-reduced PRP (LP-PRP)	Chronic tendon pathologies and intra-articular applications.

Why Alocuro Enables Precision PRP

With Alocuro’s PRO-PRP system, practitioners can precisely tailor each preparation to the indication and tissue biology. The system’s unique flexibility allows adjustment of leukocyte inclusion according to the clinical goal.

This level of control enables clinicians to:

Adjust leukocyte inclusion based on indication and tissue biology
Avoid unnecessary inflammation in joints, aesthetic treatments, and chronic tendon conditions
Deliver consistent, evidence-based outcomes using repeatable preparation protocols

In regenerative medicine, customisation is essential. Alocuro makes it simple, allowing practitioners to deliver biologically appropriate PRP for every patient and every stage of healing.

Performance Characteristics of Alocuro’s Leukocyte-Reduced PRP

(From validation conducted by S&N Pathology Clinical Trials Division)

Alocuro MSK ACDA Protocol – Mean Collection Efficiencies:

Platelet collection efficiency: 90%
Total leukocyte collection efficiency: 2.08%
Neutrophil collection efficiency: 0.16%
Lymphocyte collection efficiency: 5.18%
Red blood cell collection efficiency: 0.19%

These values demonstrate the system’s ability to deliver high platelet yield with minimal leukocyte and red cell carryover, optimised for intra-articular and chronic tendon PRP applications.

Ongoing Evidence & International Consensus

Despite broad clinical use, no universal standard exists for leukocyte thresholds in PRP. However:

The International Olympic Committee recommends full disclosure of leukocyte content in sports medicine PRP research.
LP-PRP has shown superiority in multiple RCTs for OA, tendinopathy, and aesthetic use.
Standardised PRP classification now includes leukocyte levels as a defining parameter.

Summary

Alocuro’s dual-configurable system allows clinicians to tailor PRP composition according to the biological needs of the target tissue:

Leukocyte-rich PRP – useful where antimicrobial or early inflammatory activity is desired.
Leukocyte-reduced PRP – preferred where chronic inflammation, degenerative pathology, or joint injection is involved.

This flexibility ensures every preparation aligns with evidence-based best practice and procedural precision.

Musculoskeletal Insight: PRP and Tendon Pathophysiology

Clinical research (e.g. Zhou et al.) shows:

LR-PRP may benefit early inflammatory phases but worsen outcomes in chronic degeneration by stimulating MMPs and IL-6.
LP-PRP is safer for chronic or intra-articular applications where excessive inflammation is counterproductive.
Scar formation risk may increase with high-anabolic PRP in young tendons during acute repair.

The timing and stage of healing, not just tissue type, should influence your PRP choice.